Introduction
============

Globally, breast cancer is the most frequently occurring cancer as well as the common cause of cancer death in women, with an estimated 1.7 million cases and 521 900 deaths in 2012. It accounts for 25.2% of all incidents cancers, and 14.7% of the cancer deaths among women worldwide.^[@r1]^ Globally, there has been a sharp rise in breast cancer cases. From 2008 to 2012, the incidence of breast cancer increased by more than 20%, while mortality increased by 14%.^[@r2]^

In many developing countries, the incidence of breast cancer is rising sharply due to changes in reproductive factors, lifestyle, and increased life expectancy.^[@r3],[@r4]^

In terms of mortality, and according to GLOBOCAN 2012 estimates, breast cancer is the second cause of cancer death in more developed regions while it is the most frequent cause of cancer death in women in less developed regions.^[@r1]^ Although the incidence rate of breast cancer is lower in developing countries than in most developed countries, case fatality rates are very high. This high case fatality rate is likely due to lack of awareness of the importance of early detection and treatment, and the scarcity of adequate facilities for detection and diagnosis as well as poor access to primary treatment.^[@r5]^

In Iraq during 2015, 4824 cases of breast cancer were reported accounting for 19.1% of all newly diagnosed cancers and 33.5% of the registered female cancers, with an incidence rate of 25.8 per 100 000 female population.^[@r6]^ In Basrah, breast cancer represents a significant health problem. It ranked as number one cancer among women accounting for 25.0% of all reported cases,^[@r7]^ and the current crude incidence rate is 23.7/100 000.^[@r8]^ In 2005, breast cancer accounted for 10.8% of cancer-related deaths in Basrah with a cause-specific death rate of 3.2/100 000 population.^[@r9]^

In recent decades, breast cancer incidence and survival have changed considerably in many countries. In many developed countries, despite the increasing incidence, the survival rates of breast cancer patients were substantially improved.^[@r10]^ In developing countries, women usually present late and are expected to have a limited life span.^[@r11]^

The prognosis and management prediction of breast cancer is affected by several clinical and histopathological factors including stage and grade, histological type, estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2/neu), and expression of Ki67. Each of these parameters determines the biology and aggression of tumor alone or in combination. In addition, they can predict the opportunity to treat breast cancer properly.^[@r12]^

According to the expression levels of Ki67 and the status of PR, ER, and HER2/neu, breast cancer was broadly categorized into four molecular subtypes: luminal A, luminal B, HER2/neu overexpression, and triple-negative breast cancer (TNBC). Each type marked a certain aggression and prognosis.^[@r13]^ A Chinese study showed that TNBC has a high risk of relapse and death.^[@r14]^

Lymph node status was also reported as an important prognostic variable for determining outcome in patients with ER+ breast cancer.^[@r15]^ While patients with breast cancer positive lymph node status showed a poor prognosis compared with their negative lymph node status counterparts, some of those patients responded well to treatment and attained a good survival. It is not well known whether lymph node involvement is simply a sign of tumor progression over time or whether a primary tumor's ability to metastasize is predetermined by its biology.^[@r16]^

The survival rate is an important measure of cancer severity and an essential mean for monitoring and evaluating the effectiveness of cancer control.^[@r17]^ Further, there is no information on breast cancer survival in Basrah. Therefore, we sought to determine the overall observed three-year survival rate of women with breast cancer diagnosed in 2013/2014 in Basrah, and to investigate the determinants of the survival.

Methods
=======

This was a prospective registry-based study done at the Oncology Center in Al-Sadr Teaching Hospital in Basrah. This is the only center in Basrah that delivers management services for adult cancer patients, particularly those with solid tumors.

The study population was women with histologically verified primary breast cancer (ICD-10 classification codes: C50.0--C50.9),^[@r18]^ living in Basrah and newly diagnosed and registered in the aforementioned center between 1 January 2013 and 31  December 2014.

The total number of registered cases during these two years was 605 (299 cases in 2013 and 306 cases in 2014), which represents the sample size of this study. The study sample included only Basrah inhabitant women to ensure accurate follow-up.

Data about sociodemographic characteristics such as age, residence, and occupation, in addition to information related to breast cancer characteristics (histopathology, tumor grade and stage) and treatment were extracted from Basrah Oncology Center registry records and patients' files according to a special form designed for the study. All medical records of breast cancer patients diagnosed in the period 2013--2014 were identified with the help of medical records administrative staff. In cases of incomplete medical records, additional data were searched via histopathological laboratory of Al-Sadr Teaching Hospital, Cancer Control Department, and the statistics department at Basrah General Health Directorate.

Each patient was followed-up until dead or alive at the end of the data collection period (i.e., for up to three years from the date of diagnosis to the 31 December 2017 cutoff point). Therefore, the only considered outcome in this study is survival. Information about death was gathered from the Basrah Oncology Center registry. In addition, the death registry from the Statistics Department using the patient's name was used to confirm death for all cases and those who lost contact with the center.

Duplication of data was avoided by using the patient's full four names (patient, father, grandfather, and family name) in addition to the mother's name. The data were typed first on an Excel sheet then matched and checked for any repetition both manually and electronically. The data were then transmitted into an SPSS Statistics (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.) computer file for statistical analysis.

Tumor morphology was grouped into invasive ductal carcinoma (IDC), invasive lobular carcinoma, and other types of carcinoma (including mucinous, scirrhous, medullary, lymphoma, and variants of IDC).^[@r19]^ Tumor stage was classified into four categories according to the TNM classification of malignant tumors of the 6^th^ edition of the American Joint Committee on Cancer Classification: stage I (T1N0M0), stage II (T0--1N1M0, T2N0--1M0, T3N0M0), stage III (T0--2N2M0, T3N1--2M0, T4N0--2M0, T0--4N3M0), and stage IV (T0--4N0--3M1).^[@r20]^ Tumor grade was classified into three classes (1 to 3), based on the Nottingham grading system.^[@r21]^ Observed survival rate was defined as \"the actual percentage of patients still alive at some specified time after diagnosis of cancer. It considers deaths from all causes, cancer or otherwise\".^[@r22]^ The observation time was defined as the time between the date of diagnosis and death. In the absence of an event, the observation time was censored at the end date of follow-up.^[@r23]^

Official approval for the study was obtained from the ethics committee of Basrah General Health Directorate before starting data collection.

Frequencies of sociodemographic and clinical characteristics of all patients were calculated.Survival rates were estimated by the Kaplan-Meier method, and the log-rank test was used to determine the differences in survival time in subgroups. Cox proportional hazard regression analysis was performed to assess the independent effect of various prognostic factors on survival and the risk of each of these factors. The following variables were entered in the regression model: age, morphology, grade, treatment, and stage of breast cancer. A *p*-value \< 0.050 was considered statistically significant.

Results
=======

A total of 605 women with breast cancer were included in the study. The mean age of the patients at the time of diagnosis was 50.5±12.1 years (range 22--85 years). About two-thirds (63.1%) were aged \< 55 years. The most frequent cancer type was IDC (89.8%). More than half (58.5%) of the patients were with grade 2 (moderately differentiated) breast cancers, while only 7.1% were with grade 1 (well differentiated). Similarly, only 45 (7.4%) patients presented with stage I breast cancer, whereas nearly half had advanced stages (stage III (30.2%) and stage IV (13.9%)) \[[Table 1](#t1){ref-type="table"}\].

###### Basic characteristics of the study population.

  Variables                                 n     \%
  ----------------------------------------- ----- ------
  Age, years                                      
  \< 35                                     52    8.6
  35--44                                    146   24.1
  45--54                                    184   30.4
  55--64                                    145   24.0
  ≥ 65                                      78    12.9
  Grade                                           
  Well differentiated                       43    7.1
  Moderately differentiated                 354   58.5
  Poorly differentiated                     208   34.4
  Stage                                           
  I                                         45    7.4
  II                                        293   48.4
  III                                       183   30.2
  IV                                        84    13.9
  Morphology                                      
  Ductal carcinoma                          543   89.8
  Lobular                                   24    4.0
  Others                                    38    6.3
  Treatment                                       
  Surgery                                   77    12.7
  Chemotherapy                              30    5.0
  Surgery and radiotherapy                  88    14.5
  Surgery and chemotherapy                  116   19.2
  Surgery, chemotherapy, and radiotherapy   294   48.6
  Total                                     605   100

The overall observed three-year survival rate of women with breast cancer in Basrah was 83.3% \[[Figure 1](#f1){ref-type="fig"}\].
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The cumulative three-year survival rates by the Kaplan-Meier method as a function of different prognostic factors (age, grade, stage, and morphology) are presented in [Table 2](#t2){ref-type="table"}. The highest three-year cumulative survival rate by age was among women aged 35--44 years, while the lower survival rates were among younger women (\< 35 years) and those aged^[@r3]^ 55 years. Age was not a significantpredictor of survival (*p =* 0.068). According to the tumor grade, the survival rate was lowest for the poorly differentiated tumor compared to well differentiated tumors (71.6% vs. 93.0%, *p* \< 0.001).

###### Survival rates (Kaplan-Meier analysis) of breast cancer cases in women diagnosed in Basrah during 2013--2014.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                           Cases\   Deaths\     Survival time, months   Cumulative three-year survival rate,\   *p*-value   
                                            n        n (%)                               %                                                   
  ----------------------------------------- -------- ----------- ----------------------- --------------------------------------- ----------- ----------
  Age, years                                                                                                                                 

  \< 35                                     52       11 (21.2)   33.3                    31.5--35.1                              78.8        0.068

  35--44                                    146      17 (11.6)   33.8                    32.7--34.9                              88.4        

  45--54                                    184      25 13.6)    33.6                    32.6--34.6                              86.4        

  55--64                                    145      32 (22.1)   31.6                    30.1--32.2                              77.9        

  ≥ 65                                      78       16 (20.5)   30.9                    28.6--33.4                              79.5        

  Grade                                                                                                                                      

  Well differentiated                       43       3 (7.0)     35.2                    34.3--36.1                              93.0        \< 0.001

  Moderately differentiated                 354      39 (11.0)   33.9                    33.2--34.7                              89.0        

  Poorly differentiated                     208      59 (28.4)   30.5                    29.0--31.9                              71.6        

  Stage                                                                                                                                      

  I                                         45       1 (2.2)     35.3                    33.9--36.6                              97.8        \< 0.001

  II                                        293      27 (9.2)    34.4                    33.7--35.1                              90.8        

  III                                       183      40 (21.9)   32.3                    31.1--33.5                              78.1        

  IV                                        84       33 (39.3)   27.3                    24.6--30.0                              60.7        

  Morphology                                                                                                                                 

  Ductal                                    543      92 (16.9)   32.8                    32.1--33.5                              83.1        0.528

  Lobular                                   24       2 (8.3)     34.4                    31.7--37.2                              91.7        

  Others                                    38       7 (18.4)    32.1                    29.1--35.1                              81.6        

  Treatment                                                                                                                                  

  Surgery                                   77       10 (13.0)   33.8                    32.4--35.2                              87.0        \< 0.001

  Chemotherapy                              30       14 (46.7)   25.5                    20.8--30.1                              53.3        

  Surgery and radiotherapy                  88       12 (13.6)   34.2                    32.9--35.4                              86.4        

  Surgery and chemotherapy                  116      20 (17.2)   32.6                    31.0--34.2                              82.8        

  Surgery, chemotherapy, and radiotherapy   294      45 (15.3)   33.0                    32.1--33.9                              84.7        
  -----------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval.

The stage of the tumor was adversely related to the survival rate and mean survival time. Stage I was associated with higher mean survival time (35.3 months) and survival rate (97.8%), while in women with stage IV breast cancer, the mean survival time was 27.3 months and the survival rate was 60.7%, (*p* \< 0.001). Morphology was an insignificant predictor of survival (*p =* 0.528). However, patients with lobular carcinoma showed a better survival rate and mean survival time than those with other morphology types.

Cox proportional hazard regression analysis showed that patients with stage IV breast cancer had a worse prognosis than those with stage I (hazard ratio (HR) = 4.65; 95% confidence interval (CI): 3.28--7.81; *p* \< 0.001). Similarly, patients with poorly differentiated tumors showed poorer prognosis compared with well differentiated tumors (HR = 4.10; 95% CI: 3.01--6.82; *p* \< 0.001). The use of chemotherapy alone was a significant predictor of poor prognosis. All other types of treatment showed no significant effect on prognosis \[[Table 3](#t3){ref-type="table"}\].

###### Cox proportional hazard regression analysis.

  Variables                                 Hazard ratio   95% CI   *p*-value   
  ----------------------------------------- -------------- -------- ----------- ----------
  Age, years                                                                    
  \< 35                                     1.00           \-       \-          \-
  35--44                                    1.06           0.53     2.10        0.103
  45--54                                    1.96           0.97     3.97        0.019
  55--64                                    2.58           1.17     5.65        0.050
  ≥ 65                                      2.55           0.83     6.87        0.168
  Grade                                                                         
  Well differentiated                       1.00           \-       \-          \-
  Moderately differentiated                 2.63           1.74     3.95        0.049
  Poorly differentiated                     4.10           3.01     6.82        \< 0.001
  Stage                                                                         
  I                                         1.0            \-       \-          \-
  II                                        1.95           1.22     3.11        0.024
  III                                       4.65           1.23     3.98        0.005
  IV                                        4.65           3.28     7.81        \< 0.001
  Morphology                                                                    
  Ductal                                    1.00           \-       \-          \-
  Lobular                                   0.41           0.34     1.47        0.757
  Others                                    1.43           0.45     2.67        0.414
  Treatment                                                                     
  Surgery                                   1.00           \-       \-          \-
  Chemotherapy                              3.91           2.14     7.12        \< 0.001
  Surgery and radiotherapy                  1.14           0.67     1.93        0.645
  Surgery and chemotherapy                  1.20           0.61     2.38        0.595
  Surgery, chemotherapy and, radiotherapy   1.16           0.61     2.17        0.631

CI: confidence interval.

Discussion
==========

Many factors affect the interpretation of cancer survival including accuracy and completeness of cancer registration, the completeness of follow-up, tumor factors like stage and grade at diagnosis, and personal characteristics like age at diagnosis.^[@r24]^

This study showed that the overall three-year observed survival rate was 83.3%. This result is comparable to that reported in Saudi Arabia (85%)^[@r25]^ and Iran (82.4%).^[@r26]^ However, it is better than that reported in Jordan (70.2%)^[@r27]^ and Thailand (59.9%).^[@r28]^

Vast differences in breast cancer survival between countries have been reported, depending on the availability of screening and diagnostic facilities and advances in treatment modalities.^[@r29]^ One study investigated the three-year breast cancer survival in six high-income countries (Australia, Canada, Denmark, Norway, Sweden, and the UK) during 2000--2007 and showed that the age-standardized three-year net survival was 87--89% in the UK and Denmark, and 91--94% in the other four countries.^[@r30]^

The five-year survival rate ranges from more than 80% in developed countries (such as North America, Sweden, and Japan) to about 60% in middle-income countries and \< 40% in low-income countries.^[@r31]^

Such variation in survival between developed and developing countries is attributed to the challenges that developing countries face in the application of the four key components to controlling cancer. These were stated by the World Health Organization and include cancer prevention, early detection, diagnosis, and treatment with palliation.^[@r32]^ In addition, other factors such as differences in population structure (life expectancy),^[@r33]^ low access to screening,^[@r34]^ lower socioeconomic status,^[@r35]^ low access to high-quality healthcare, poor treatment adherence,^[@r36]^ poor lifestyle modification after a cancer diagnosis,^[@r37]^ and variation in tumor biology contribute to this variation.^[@r38]^

A debate about the impact of young age at diagnosis on the survival of women with breast cancer has been long documented.^[@r39]^ Although younger women (\< 35 years old) and older women (^[@r3]^ 55 years old) showed a lower survival rate than those aged 35--44 years, this study showed that age was not associated with survival. This result agrees with that of many previous studies.^[@r26],[@r40]^ On the contrary, many studies indicated younger age as a factor associated with poor survival.^[@r27],[@r40]^ The age effect may be distorted by the fact that the outcome was death from all causes rather than breast cancer deaths. It is also likely that the follow-up time is too short to document such an age effect.

The results of this study showed that the three-year survival rate was significantly poorer in patients with stage IV breast cancer than in patients with stage I. These results are in agreement with that reported in both developed and developing countries. In developed countries, despite the advances in biomedical researches and early detection and treatment, stage IV accounts for a large proportion of mortality.^[@r41]^

In developing countries including Iraq, women with breast cancer usually presented with advanced stage and consequently poor prognosis.^[@r42]^ In Jordan, the five-year survival for stage IV patients was 5.8% vs. 96% for those with stage I breast cancer.^[@r27]^ A study in Thailand showed that the five-year survival for early stage cancer was (60%; 95% CI: 0.51--0.67) higher than the late stage (27%; 95% CI: 0.19--0.34).^[@r28]^ In Pakistan, the five-year stage-specific survival was 100%, 88%, 58% for stage I, II, III respectively, and the median survival for stage IV patients was 18 months.^[@r43]^

This study showed that there was a significant association between the grade of breast cancer and survival, which has been reported previously.^[@r43]^ Patients with grade 3 (poorly differentiated tumors) had an increased mortality risk compared to those with grade 1 (well differentiated) (HR = 4.10; 95% CI: 3.01--6.82; *p* \< 0.001).

In agreement with a study done in Jordan,^[@r27]^ tumor morphology showed no statistically significant effect on survival. Nevertheless, the lobular subtype of breast cancer was found to be less aggressive than other types of breast cancer in accordance with previous reports.^[@r44]^

In agreement with what was previously reported in Jordan,^[@r27]^ Brazil,^[@r45]^ and Iran^[@r24]^ patients who were surgically treated showed better survival than those treated with combined therapy of surgery, radiotherapy, and chemotherapy but without significant difference. Contrarily to that reported in Oman,^[@r42]^ chemotherapy alone was associated with a worse prognosis. Chemotherapy or medical treatment is mostly considered in metastatic breast cancer; therefore, it may reflect the severity of cancer, which is responsible for the high risk of death.^[@r46]^

Several limitations of this study should be addressed. First, incompleteness in death registries cannot be excluded entirely. However, death is a recognizable event, and the fact of death is usually ascertained in Islamic countries for legal, religious, and social issues (such as a proof for burial or inheritance claims).^[@r47]^ Some inaccuracies may occur about the cause of death, particularly in elderly people. In this study, the aim was not to calculate the cause-specific death rate, but to calculate mortality among women with breast cancer regardless of the cause. Therefore, the effect of such a limitation might be reduced. Being a registry-based study, many prognostic factors such as PR, ER, HER2/neu statuses, socioeconomic status, and educational level were completely missing. Furthermore, information on occupation was either incomplete or written incorrectly, so these variables were not analyzed. Therefore, their influence on survival will be difficult to gauge. The strength of the study is that it was the first to assess the survival rate of breast cancer in Basrah.

Conclusion
==========

The three-year survival rate of women with breast cancer in Basrah was comparable to that in some developing countries. However, it was poorer than that in developed countries. Advanced stage and grade of the tumor were significantly associated with poor survival. Health care providers must be more aware of different treatment modalities used to treat cancer in addition to the development of tertiary care to improve the survival of patients with breast cancer. Educational programs for women about breast self-examination and implementation of screening programs are vital for early detection of breast cancer. Further studies are needed to ensure the inclusion of other variables such as lymph node status ER, PR, and HER2/neu expression.
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